Literature DB >> 33024304

Problematic breast tumors reassessed in light of novel molecular data.

Fresia Pareja1, Britta Weigelt1, Jorge S Reis-Filho2.   

Abstract

Breast cancer is a vastly heterogeneous disease encompassing a panoply of special histological subtypes. Although rare breast tumors have largely not been investigated systematically in large scale genomics series, recent studies have shed light on the genetic underpinnings of special histologic subtypes of breast cancer. Genomic analyses of estrogen receptor-positive special histologic types of breast cancer have not resulted in the identification of novel pathognomonic genetic alterations in addition to the confirmation of the presence of CDH1 loss-of-function mutations in invasive lobular carcinomas. By contrast, the analyses of triple-negative breast cancers have demonstrated that low-grade triple-negative breast cancers categorically differ from the common forms of high-grade triple-negative disease biologically and phenotypically and are underpinned by specific fusion genes or hotspot mutations. A subset of low-grade triple-negative disease has been shown to harbor highly recurrent if not pathognomonic genetic alterations, such as ETV6-NTRK3 fusion gene in secretory carcinomas, the MYB-NFIB fusion gene, MYBL1 rearrangements or MYB gene amplification in adenoid cystic carcinomas, and HRAS Q61 hotspot mutations coupled with mutations in PI3K pathway genes in estrogen receptor-negative adenomyoepitheliomas. A subset of these pathognomonic genetic alterations (e.g., NTRK1/2/3 fusion genes) now constitute an FDA approved indication for the use of TRK inhibitors in the advanced/metastatic setting. These studies have also corroborated that salivary gland-like tumors of the breast, other than acinic cell carcinomas, harbor the repertoire of somatic genetic alterations detected in their salivary gland counterparts. Reassuringly, the systematic study of special histologic types of breast cancer utilizing state-of-the-art sequencing approaches, rather than rendering pathology obsolete, has actually strengthened the importance of breast cancer histologic typing and is providing additional ancillary markers for the diagnosis of these rare but fascinating entities.

Entities:  

Year:  2020        PMID: 33024304     DOI: 10.1038/s41379-020-00693-7

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  85 in total

Review 1.  Histological types of breast cancer: how special are they?

Authors:  Britta Weigelt; Felipe C Geyer; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2010-04-18       Impact factor: 6.603

Review 2.  Tackling the diversity of triple-negative breast cancer.

Authors:  Nicholas C Turner; Jorge S Reis-Filho
Journal:  Clin Cancer Res       Date:  2013-12-01       Impact factor: 12.531

3.  Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study.

Authors:  Teri A Longacre; Marguerite Ennis; Louise A Quenneville; Anita L Bane; Ira J Bleiweiss; Beverley A Carter; Edison Catelano; Michael R Hendrickson; Hanina Hibshoosh; Lester J Layfield; Lorenzo Memeo; Hong Wu; Frances P O'malley
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

4.  Genomic Characterization of Primary Invasive Lobular Breast Cancer.

Authors:  Christine Desmedt; Gabriele Zoppoli; Gunes Gundem; Giancarlo Pruneri; Denis Larsimont; Marco Fornili; Debora Fumagalli; David Brown; Françoise Rothé; Delphine Vincent; Naima Kheddoumi; Ghizlane Rouas; Samira Majjaj; Sylvain Brohée; Peter Van Loo; Patrick Maisonneuve; Roberto Salgado; Thomas Van Brussel; Diether Lambrechts; Ron Bose; Otto Metzger; Christine Galant; François Bertucci; Martine Piccart-Gebhart; Giuseppe Viale; Elia Biganzoli; Peter J Campbell; Christos Sotiriou
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

5.  Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer.

Authors:  Bastien Nguyen; Isabelle Veys; Sophia Leduc; Yacine Bareche; Samira Majjaj; David N Brown; Bram Boeckx; Diether Lambrechts; Christos Sotiriou; Denis Larsimont; Christine Desmedt
Journal:  J Natl Cancer Inst       Date:  2019-07-01       Impact factor: 13.506

6.  Genetic interactions in cancer progression and treatment.

Authors:  Alan Ashworth; Christopher J Lord; Jorge S Reis-Filho
Journal:  Cell       Date:  2011-04-01       Impact factor: 41.582

7.  The Genomic Landscape of Mucinous Breast Cancer.

Authors:  Fresia Pareja; Ju Youn Lee; David N Brown; Salvatore Piscuoglio; Rodrigo Gularte-Mérida; Pier Selenica; Arnaud Da Cruz Paula; Sasi Arunachalam; Rahul Kumar; Felipe C Geyer; Catarina Silveira; Edaise M da Silva; Anqi Li; Caterina Marchiò; Charlotte K Y Ng; Odette Mariani; Laetitia Fuhrmann; Hannah Y Wen; Larry Norton; Anne Vincent-Salomon; Edi Brogi; Jorge S Reis-Filho; Britta Weigelt
Journal:  J Natl Cancer Inst       Date:  2019-07-01       Impact factor: 13.506

Review 8.  Histological and molecular types of breast cancer: is there a unifying taxonomy?

Authors:  Britta Weigelt; Jorge S Reis-Filho
Journal:  Nat Rev Clin Oncol       Date:  2009-12       Impact factor: 66.675

9.  Refinement of breast cancer classification by molecular characterization of histological special types.

Authors:  B Weigelt; H M Horlings; B Kreike; M M Hayes; M Hauptmann; L F A Wessels; D de Jong; M J Van de Vijver; L J Van't Veer; J L Peterse
Journal:  J Pathol       Date:  2008-10       Impact factor: 7.996

10.  Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma.

Authors:  Ju Youn Lee; Michail Schizas; Felipe C Geyer; Pier Selenica; Salvatore Piscuoglio; Rita A Sakr; Charlotte K Y Ng; Jose V Scarpa Carniello; Russell Towers; Dilip D Giri; Victor P de Andrade; Anastasios D Papanastasiou; Agnes Viale; Reuben S Harris; David B Solit; Britta Weigelt; Jorge S Reis-Filho; Tari A King
Journal:  Clin Cancer Res       Date:  2018-09-05       Impact factor: 12.531

View more
  9 in total

1.  Metaplastic Matrix-Producing Carcinoma and Apocrine Lobular Carcinoma In Situ Associated with Microglandular Adenosis: A Unique Case Report.

Authors:  Nektarios Koufopoulos; Dionysios Dimas; Foteini Antoniadou; Kyparissia Sitara; Dimitrios Balalis; Ioannis Boutas; Alina Roxana Gouloumis; Adamantia Kontogeorgi; Lubna Khaldi
Journal:  Diagnostics (Basel)       Date:  2022-06-13

Review 2.  Pathogenesis of Triple-Negative Breast Cancer.

Authors:  Fatemeh Derakhshan; Jorge S Reis-Filho
Journal:  Annu Rev Pathol       Date:  2022-01-24       Impact factor: 32.350

3.  The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features.

Authors:  Christopher J Schwartz; Edi Brogi; Antonio Marra; Arnaud F Da Cruz Paula; Gouri J Nanjangud; Edaise M da Silva; Sujata Patil; Shreena Shah; Katia Ventura; Pedram Razavi; Larry Norton; Timothy D'alfonso; Britta Weigelt; Fresia Pareja; Jorge S Reis-Filho; Hannah Y Wen
Journal:  Mod Pathol       Date:  2021-10-01       Impact factor: 8.209

Review 4.  Triple-negative breast carcinomas of low malignant potential: review on diagnostic criteria and differential diagnoses.

Authors:  L Cima; H Kaya; C Marchiò; R Nishimura; H Y Wen; V P Fabbri; M P Foschini
Journal:  Virchows Arch       Date:  2021-08-30       Impact factor: 4.535

Review 5.  Fusion-associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance.

Authors:  Suet Kee Loo; Megan E Yates; Sichun Yang; Steffi Oesterreich; Adrian V Lee; Xiao-Song Wang
Journal:  Genes Chromosomes Cancer       Date:  2022-02-17       Impact factor: 5.006

6.  The BA-BCS 2021: An Initial "Trial" for Integrating Basic Science and Medical Progress on Breast Cancer in a Latin-American Country.

Authors:  Edith Kordon; Claudia Lanari; Pablo Mando; Virginia Novaro; Mario Rossi; Marina Simian
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-10-12       Impact factor: 2.673

7.  Long non-coding RNA MIR200CHG promotes breast cancer proliferation, invasion, and drug resistance by interacting with and stabilizing YB-1.

Authors:  Li Tang; Da Wei; Xinyu Xu; Xuelian Mao; Dongping Mo; Linping Yan; Weiguo Xu; Feng Yan
Journal:  NPJ Breast Cancer       Date:  2021-07-16

Review 8.  Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations.

Authors:  Dara S Ross; Fresia Pareja
Journal:  Surg Pathol Clin       Date:  2021-07-08

9.  Biglycan Promotes Cancer Stem Cell Properties, NFκB Signaling and Metastatic Potential in Breast Cancer Cells.

Authors:  Kanakaraju Manupati; Ritama Paul; Mingang Hao; Michael Haas; Zhaoqun Christine Bian; Tammy M Holm; Jun-Lin Guan; Syn Kok Yeo
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.